How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "7624"
  ["article_id"]=>
  string(4) "7624"
  [1]=>
  string(117) "Seattle Genetics gets FDA priority review for tucatinib in locally advanced or metastatic HER2-positive breast cancer"
  ["article_title"]=>
  string(117) "Seattle Genetics gets FDA priority review for tucatinib in locally advanced or metastatic HER2-positive breast cancer"
  [2]=>
  string(150) "This NDA requests FDA approval of tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresecta"
  ["short_description"]=>
  string(150) "This NDA requests FDA approval of tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresecta"
  [3]=>
  string(722) "
This NDA requests FDA approval of tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients 
&#nl
The post Seattle Genetics gets FDA priority review for tucatinib in locally advanced or metastatic HER2-positive breast cancer appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(722) "
This NDA requests FDA approval of tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients 
&#nl
The post Seattle Genetics gets FDA priority review for tucatinib in locally advanced or metastatic HER2-positive breast cancer appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(170) "https://www.pharmaceutical-business-review.com/news/seattle-genetics-gets-fda-priority-review-for-tucatinib-in-locally-advanced-or-metastatic-her2-positive-breast-cancer/"
  ["blog_url"]=>
  string(170) "https://www.pharmaceutical-business-review.com/news/seattle-genetics-gets-fda-priority-review-for-tucatinib-in-locally-advanced-or-metastatic-her2-positive-breast-cancer/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-18 11:37:47"
  ["create_at"]=>
  string(19) "2020-02-18 11:37:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Seattle Genetics gets FDA priority review for tucatinib in locally advanced or metastatic

This NDA requests FDA approval of tucatinib in combination with trastuzumab and capecitabine for treatment of patient

array(40) {
  [0]=>
  string(4) "7625"
  ["article_id"]=>
  string(4) "7625"
  [1]=>
  string(154) "The US FDA accepts for priority review Bristol-Myers Squibb’s BLA for liso-cel for adult patients with relapsed or refractory large B-cell lymphoma"
  ["article_title"]=>
  string(154) "The US FDA accepts for priority review Bristol-Myers Squibb’s BLA for liso-cel for adult patients with relapsed or refractory large B-cell lymphoma"
  [2]=>
  string(154) "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 17, 2020. “There remains a critical need for additional therapies in la"
  ["short_description"]=>
  string(154) "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 17, 2020. “There remains a critical need for additional therapies in la"
  [3]=>
  string(737) "
The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 17, 2020. “There remains a critical need for additional therapies in large B-cell 
&#nl
The post The US FDA accepts for priority review Bristol-Myers Squibb’s BLA for liso-cel for adult patients with relapsed or refractory large B-cell lymphoma appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(737) "
The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 17, 2020. “There remains a critical need for additional therapies in large B-cell 
&#nl
The post The US FDA accepts for priority review Bristol-Myers Squibb’s BLA for liso-cel for adult patients with relapsed or refractory large B-cell lymphoma appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(199) "https://www.pharmaceutical-business-review.com/news/the-us-fda-accepts-for-priority-review-bristol-myers-squibbs-bla-for-liso-cel-for-adult-patients-with-relapsed-or-refractory-large-b-cell-lymphoma/"
  ["blog_url"]=>
  string(199) "https://www.pharmaceutical-business-review.com/news/the-us-fda-accepts-for-priority-review-bristol-myers-squibbs-bla-for-liso-cel-for-adult-patients-with-relapsed-or-refractory-large-b-cell-lymphoma/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-18 11:37:47"
  ["create_at"]=>
  string(19) "2020-02-18 11:37:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

The US FDA accepts for priority review Bristol-Myers Squibb’s BLA for liso-cel for

The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 17, 2020. “There remains a critica

array(40) {
  [0]=>
  string(4) "7626"
  ["article_id"]=>
  string(4) "7626"
  [1]=>
  string(76) "Roche gets Chinese approval for Tecentriq plus chemotherapy to treat ES-SCLC"
  ["article_title"]=>
  string(76) "Roche gets Chinese approval for Tecentriq plus chemotherapy to treat ES-SCLC"
  [2]=>
  string(150) "Tecentriq is a monoclonal antibody designed to bind with PD-L1 protein that is expressed on tumour cells and tumour-infiltrating immune cells, restric"
  ["short_description"]=>
  string(150) "Tecentriq is a monoclonal antibody designed to bind with PD-L1 protein that is expressed on tumour cells and tumour-infiltrating immune cells, restric"
  [3]=>
  string(575) "
Tecentriq is a monoclonal antibody designed to bind with PD-L1 protein that is expressed on tumour cells and tumour-infiltrating immune cells, restricting its interactions with both PD-1 and 
&#nl
The post Roche gets Chinese approval for Tecentriq plus chemotherapy to treat ES-SCLC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(575) "
Tecentriq is a monoclonal antibody designed to bind with PD-L1 protein that is expressed on tumour cells and tumour-infiltrating immune cells, restricting its interactions with both PD-1 and 
&#nl
The post Roche gets Chinese approval for Tecentriq plus chemotherapy to treat ES-SCLC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(89) "https://www.pharmaceutical-business-review.com/news/roche-chinese-tecentriq-chemotherapy/"
  ["blog_url"]=>
  string(89) "https://www.pharmaceutical-business-review.com/news/roche-chinese-tecentriq-chemotherapy/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-18 11:37:47"
  ["create_at"]=>
  string(19) "2020-02-18 11:37:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Roche gets Chinese approval for Tecentriq plus chemotherapy to treat ES-SCLC

Tecentriq is a monoclonal antibody designed to bind with PD-L1 protein that is expressed on tumour cells and tumour-i

array(40) {
  [0]=>
  string(4) "7627"
  ["article_id"]=>
  string(4) "7627"
  [1]=>
  string(58) "ALX Oncology announces closing of $105m Series C financing"
  ["article_title"]=>
  string(58) "ALX Oncology announces closing of $105m Series C financing"
  [2]=>
  string(150) "Vivo Capital was the lead investor with other new investors including funds managed by Logos Capital, Janus Henderson, Foresite Capital, Cormorant Ass"
  ["short_description"]=>
  string(150) "Vivo Capital was the lead investor with other new investors including funds managed by Logos Capital, Janus Henderson, Foresite Capital, Cormorant Ass"
  [3]=>
  string(583) "
Vivo Capital was the lead investor with other new investors including funds managed by Logos Capital, Janus Henderson, Foresite Capital, Cormorant Asset Management, BVF Partners, and investor HBM 
&#nl
The post ALX Oncology announces closing of $105m Series C financing appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(583) "
Vivo Capital was the lead investor with other new investors including funds managed by Logos Capital, Janus Henderson, Foresite Capital, Cormorant Asset Management, BVF Partners, and investor HBM 
&#nl
The post ALX Oncology announces closing of $105m Series C financing appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(110) "https://www.pharmaceutical-business-review.com/news/alx-oncology-announces-closing-of-105m-series-c-financing/"
  ["blog_url"]=>
  string(110) "https://www.pharmaceutical-business-review.com/news/alx-oncology-announces-closing-of-105m-series-c-financing/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-18 11:37:47"
  ["create_at"]=>
  string(19) "2020-02-18 11:37:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

ALX Oncology announces closing of $105m Series C financing

Vivo Capital was the lead investor with other new investors including funds managed by Logos Capital, Janus Henderson

array(40) {
  [0]=>
  string(4) "7628"
  ["article_id"]=>
  string(4) "7628"
  [1]=>
  string(154) "Deciphera Pharmaceuticals announces US FDA acceptance of NDA and priority review for ripretinib in patients with advanced gastrointestinal stromal tumours"
  ["article_title"]=>
  string(154) "Deciphera Pharmaceuticals announces US FDA acceptance of NDA and priority review for ripretinib in patients with advanced gastrointestinal stromal tumours"
  [2]=>
  string(150) "The FDA granted Priority Review for the NDA, which provides for a six-month review, and assigned a Prescription Drug User Fee Act (PDUFA) target actio"
  ["short_description"]=>
  string(150) "The FDA granted Priority Review for the NDA, which provides for a six-month review, and assigned a Prescription Drug User Fee Act (PDUFA) target actio"
  [3]=>
  string(747) "
The FDA granted Priority Review for the NDA, which provides for a six-month review, and assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 
&#nl
The post Deciphera Pharmaceuticals announces US FDA acceptance of NDA and priority review for ripretinib in patients with advanced gastrointestinal stromal tumours appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(747) "
The FDA granted Priority Review for the NDA, which provides for a six-month review, and assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 
&#nl
The post Deciphera Pharmaceuticals announces US FDA acceptance of NDA and priority review for ripretinib in patients with advanced gastrointestinal stromal tumours appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(207) "https://www.pharmaceutical-business-review.com/news/deciphera-pharmaceuticals-announces-us-fda-acceptance-of-nda-and-priority-review-for-ripretinib-in-patients-with-advanced-gastrointestinal-stromal-tumours/"
  ["blog_url"]=>
  string(207) "https://www.pharmaceutical-business-review.com/news/deciphera-pharmaceuticals-announces-us-fda-acceptance-of-nda-and-priority-review-for-ripretinib-in-patients-with-advanced-gastrointestinal-stromal-tumours/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-18 11:37:47"
  ["create_at"]=>
  string(19) "2020-02-18 11:37:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Deciphera Pharmaceuticals announces US FDA acceptance of NDA and priority review for ripre

The FDA granted Priority Review for the NDA, which provides for a six-month review, and assigned a Prescription Drug 

array(40) {
  [0]=>
  string(4) "7629"
  ["article_id"]=>
  string(4) "7629"
  [1]=>
  string(79) "Merck’s Keytruda plus chemotherapy meets primary endpoint in mTNBC trial"
  ["article_title"]=>
  string(79) "Merck’s Keytruda plus chemotherapy meets primary endpoint in mTNBC trial"
  [2]=>
  string(150) "Keytruda plus chemotherapy achieved one of its dual primary endpoints of PFS in patients with mTNBC whose tumours expressed PD-L1. Keytruda, an anti-P"
  ["short_description"]=>
  string(150) "Keytruda plus chemotherapy achieved one of its dual primary endpoints of PFS in patients with mTNBC whose tumours expressed PD-L1. Keytruda, an anti-P"
  [3]=>
  string(562) "
Keytruda plus chemotherapy achieved one of its dual primary endpoints of PFS in patients with mTNBC whose tumours expressed PD-L1. Keytruda, an anti-PD-1 therapy, works by blocking the 
&#nl
The post Merck’s Keytruda plus chemotherapy meets primary endpoint in mTNBC trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(562) "
Keytruda plus chemotherapy achieved one of its dual primary endpoints of PFS in patients with mTNBC whose tumours expressed PD-L1. Keytruda, an anti-PD-1 therapy, works by blocking the 
&#nl
The post Merck’s Keytruda plus chemotherapy meets primary endpoint in mTNBC trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/merck-keytruda-mtnbc-trial/"
  ["blog_url"]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/merck-keytruda-mtnbc-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-18 11:37:47"
  ["create_at"]=>
  string(19) "2020-02-18 11:37:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Merck’s Keytruda plus chemotherapy meets primary endpoint in mTNBC trial

Keytruda plus chemotherapy achieved one of its dual primary endpoints of PFS in patients with mTNBC whose tumours exp

array(40) {
  [0]=>
  string(4) "7719"
  ["article_id"]=>
  string(4) "7719"
  [1]=>
  string(93) "Cornerstone to Showcase AI-powered Innovations Disrupting HR at Learning Technologies UK 2020"
  ["article_title"]=>
  string(93) "Cornerstone to Showcase AI-powered Innovations Disrupting HR at Learning Technologies UK 2020"
  [2]=>
  string(150) "Cornerstone client Novartis will also be sharing how the company developed a culture of curiosity amongst its workforce London — 04 February, 20"
  ["short_description"]=>
  string(150) "Cornerstone client Novartis will also be sharing how the company developed a culture of curiosity amongst its workforce London — 04 February, 20"
  [3]=>
  string(571) "Cornerstone client Novartis will also be sharing how the company developed a culture of curiosity amongst its workforce London — 04 February, 2020 – Cornerstone OnDemand, Inc. (NASDAQ:CSOD), a global leader in people development solutions, today announced the company’s participation at Learning Technologies UK 2020, taking place at the ExCel, London on 12-13 February, 2020. Cornerstone invites conference delegates to Stand G10 in Hall N2-N6, to experience the company’s world-class Learning Suite and Content Anytime...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(571) "Cornerstone client Novartis will also be sharing how the company developed a culture of curiosity amongst its workforce London — 04 February, 2020 – Cornerstone OnDemand, Inc. (NASDAQ:CSOD), a global leader in people development solutions, today announced the company’s participation at Learning Technologies UK 2020, taking place at the ExCel, London on 12-13 February, 2020. Cornerstone invites conference delegates to Stand G10 in Hall N2-N6, to experience the company’s world-class Learning Suite and Content Anytime...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "4"
  ["category"]=>
  string(1) "4"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "65"
  ["rss_id"]=>
  string(2) "65"
  [14]=>
  string(93) "http://www.realwire.com/releases/Cornerstone-to-Showcase-AI-powered-Innovations-Disrupting-HR"
  ["blog_url"]=>
  string(93) "http://www.realwire.com/releases/Cornerstone-to-Showcase-AI-powered-Innovations-Disrupting-HR"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-18 11:38:14"
  ["create_at"]=>
  string(19) "2020-02-18 11:38:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Cornerstone to Showcase AI-powered Innovations Disrupting HR at Learning Technologies UK 2

Cornerstone client Novartis will also be sharing how the company developed a culture of curiosity amongst its workforce 

array(40) {
  [0]=>
  string(4) "7720"
  ["article_id"]=>
  string(4) "7720"
  [1]=>
  string(106) "ASOS and Verint among 300 new customers for e-days as companies double down on absence management for 2020"
  ["article_title"]=>
  string(106) "ASOS and Verint among 300 new customers for e-days as companies double down on absence management for 2020"
  [2]=>
  string(150) "Software provider sees customers like AXA move towards full integration of absence management software ASOS, Campari and John Clark Motor Group among "
  ["short_description"]=>
  string(150) "Software provider sees customers like AXA move towards full integration of absence management software ASOS, Campari and John Clark Motor Group among "
  [3]=>
  string(536) "Software provider sees customers like AXA move towards full integration of absence management software ASOS, Campari and John Clark Motor Group among major signings e-days enjoys 30% business growth in 2019 28th January 2020. Nottingham, UK: e-days, the UK tech start-up backed by Palatine Private Equity’s ‘Impact fund’, has today announced that the online retail giant ASOS and analytics software provider Verint were among 300 new customers that started using the e-days platform in 2019....&#nl&#nlSource: RealWire"
  ["description"]=>
  string(536) "Software provider sees customers like AXA move towards full integration of absence management software ASOS, Campari and John Clark Motor Group among major signings e-days enjoys 30% business growth in 2019 28th January 2020. Nottingham, UK: e-days, the UK tech start-up backed by Palatine Private Equity’s ‘Impact fund’, has today announced that the online retail giant ASOS and analytics software provider Verint were among 300 new customers that started using the e-days platform in 2019....&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "4"
  ["category"]=>
  string(1) "4"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "65"
  ["rss_id"]=>
  string(2) "65"
  [14]=>
  string(83) "http://www.realwire.com/releases/ASOS-and-Verint-among-300-new-customers-for-e-days"
  ["blog_url"]=>
  string(83) "http://www.realwire.com/releases/ASOS-and-Verint-among-300-new-customers-for-e-days"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-18 11:38:14"
  ["create_at"]=>
  string(19) "2020-02-18 11:38:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

ASOS and Verint among 300 new customers for e-days as companies double down on absence man

Software provider sees customers like AXA move towards full integration of absence management software ASOS, Campari and

array(40) {
  [0]=>
  string(4) "7884"
  ["article_id"]=>
  string(4) "7884"
  [1]=>
  string(98) "Harbour BioMed receives FDA IND approval for phase 2 trial and orphan drug designation for HBM9167"
  ["article_title"]=>
  string(98) "Harbour BioMed receives FDA IND approval for phase 2 trial and orphan drug designation for HBM9167"
  [2]=>
  string(159) "Separately, the Agency’s Office of Orphan Products Development granted HBM9167 Orphan Drug Designation (ODD) for the use in treating NPC. “Nasopha"
  ["short_description"]=>
  string(159) "Separately, the Agency’s Office of Orphan Products Development granted HBM9167 Orphan Drug Designation (ODD) for the use in treating NPC. “Nasopha"
  [3]=>
  string(668) "
Separately, the Agency’s Office of Orphan Products Development granted HBM9167 Orphan Drug Designation (ODD) for the use in treating NPC. “Nasopharyngeal cancer is a tumor type for which 
&#nl
The post Harbour BioMed receives FDA IND approval for phase 2 trial and orphan drug designation for HBM9167 appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(668) "
Separately, the Agency’s Office of Orphan Products Development granted HBM9167 Orphan Drug Designation (ODD) for the use in treating NPC. “Nasopharyngeal cancer is a tumor type for which 
&#nl
The post Harbour BioMed receives FDA IND approval for phase 2 trial and orphan drug designation for HBM9167 appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(151) "https://www.pharmaceutical-business-review.com/news/harbour-biomed-receives-fda-ind-approval-for-phase-2-trial-and-orphan-drug-designation-for-hbm9167/"
  ["blog_url"]=>
  string(151) "https://www.pharmaceutical-business-review.com/news/harbour-biomed-receives-fda-ind-approval-for-phase-2-trial-and-orphan-drug-designation-for-hbm9167/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-28 18:48:56"
  ["create_at"]=>
  string(19) "2020-02-28 18:48:56"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Harbour BioMed receives FDA IND approval for phase 2 trial and orphan drug designation for

Separately, the Agency’s Office of Orphan Products Development granted HBM9167 Orphan Drug Designation (ODD) f

array(40) {
  [0]=>
  string(4) "7885"
  ["article_id"]=>
  string(4) "7885"
  [1]=>
  string(82) "Boehringer Ingelheim enters discovery stage collaboration with Trutino Biosciences"
  ["article_title"]=>
  string(82) "Boehringer Ingelheim enters discovery stage collaboration with Trutino Biosciences"
  [2]=>
  string(155) "Under the terms of strategic alliance, Boehringer Ingelheim gains access to Trutino’s ODC platform technology for the generation and development of "
  ["short_description"]=>
  string(155) "Under the terms of strategic alliance, Boehringer Ingelheim gains access to Trutino’s ODC platform technology for the generation and development of "
  [3]=>
  string(628) "
Under the terms of strategic alliance, Boehringer Ingelheim gains access to Trutino’s ODC platform technology for the generation and development of up to three new ODC candidates. This 
&#nl
The post Boehringer Ingelheim enters discovery stage collaboration with Trutino Biosciences appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(628) "
Under the terms of strategic alliance, Boehringer Ingelheim gains access to Trutino’s ODC platform technology for the generation and development of up to three new ODC candidates. This 
&#nl
The post Boehringer Ingelheim enters discovery stage collaboration with Trutino Biosciences appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(135) "https://www.pharmaceutical-business-review.com/news/boehringer-ingelheim-enters-discovery-stage-collaboration-with-trutino-biosciences/"
  ["blog_url"]=>
  string(135) "https://www.pharmaceutical-business-review.com/news/boehringer-ingelheim-enters-discovery-stage-collaboration-with-trutino-biosciences/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-28 18:48:56"
  ["create_at"]=>
  string(19) "2020-02-28 18:48:56"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Boehringer Ingelheim enters discovery stage collaboration with Trutino Biosciences

Under the terms of strategic alliance, Boehringer Ingelheim gains access to Trutino’s ODC platform technology 

array(40) {
  [0]=>
  string(4) "7886"
  ["article_id"]=>
  string(4) "7886"
  [1]=>
  string(77) "GSK, Innoviva seek EMA approval for Trelegy Ellipta to treat asthma in adults"
  ["article_title"]=>
  string(77) "GSK, Innoviva seek EMA approval for Trelegy Ellipta to treat asthma in adults"
  [2]=>
  string(150) "The regulator has accepted the application for the use of once-daily and single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidin"
  ["short_description"]=>
  string(150) "The regulator has accepted the application for the use of once-daily and single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidin"
  [3]=>
  string(602) "
The regulator has accepted the application for the use of once-daily and single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) to treat asthma in adults. Trelegy Ellipta 
&#nl
The post GSK, Innoviva seek EMA approval for Trelegy Ellipta to treat asthma in adults appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(602) "
The regulator has accepted the application for the use of once-daily and single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) to treat asthma in adults. Trelegy Ellipta 
&#nl
The post GSK, Innoviva seek EMA approval for Trelegy Ellipta to treat asthma in adults appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/gsk-innoviva-trelegy-ellipta-2/"
  ["blog_url"]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/gsk-innoviva-trelegy-ellipta-2/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-28 18:48:57"
  ["create_at"]=>
  string(19) "2020-02-28 18:48:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

GSK, Innoviva seek EMA approval for Trelegy Ellipta to treat asthma in adults

The regulator has accepted the application for the use of once-daily and single-inhaler triple therapy, Trelegy Ellip

array(40) {
  [0]=>
  string(4) "7887"
  ["article_id"]=>
  string(4) "7887"
  [1]=>
  string(122) "FDA advisory committee votes in favour of Lilly’s CYRAMZA as first-line treatment for metastatic EGFR-mutated NSCLC"
  ["article_title"]=>
  string(122) "FDA advisory committee votes in favour of Lilly’s CYRAMZA as first-line treatment for metastatic EGFR-mutated NSCLC"
  [2]=>
  string(150) "“Given the unmet need that remains in treating metastatic EGFR-mutated non-small cell lung cancer, we are encouraged that the majority of these "
  ["short_description"]=>
  string(150) "“Given the unmet need that remains in treating metastatic EGFR-mutated non-small cell lung cancer, we are encouraged that the majority of these "
  [3]=>
  string(698) "
“Given the unmet need that remains in treating metastatic EGFR-mutated non-small cell lung cancer, we are encouraged that the majority of these experts agree CYRAMZA plus erlotinib has 
&#nl
The post FDA advisory committee votes in favour of Lilly’s CYRAMZA as first-line treatment for metastatic EGFR-mutated NSCLC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(698) "
“Given the unmet need that remains in treating metastatic EGFR-mutated non-small cell lung cancer, we are encouraged that the majority of these experts agree CYRAMZA plus erlotinib has 
&#nl
The post FDA advisory committee votes in favour of Lilly’s CYRAMZA as first-line treatment for metastatic EGFR-mutated NSCLC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(167) "https://www.pharmaceutical-business-review.com/news/fda-advisory-committee-votes-in-favour-of-lillys-cyramza-as-first-line-treatment-for-metastatic-egfr-mutated-nsclc/"
  ["blog_url"]=>
  string(167) "https://www.pharmaceutical-business-review.com/news/fda-advisory-committee-votes-in-favour-of-lillys-cyramza-as-first-line-treatment-for-metastatic-egfr-mutated-nsclc/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-28 18:48:57"
  ["create_at"]=>
  string(19) "2020-02-28 18:48:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA advisory committee votes in favour of Lilly’s CYRAMZA as first-line treatment f

“Given the unmet need that remains in treating metastatic EGFR-mutated non-small cell lung cancer, we are encou